Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients

Table 1 Baseline demographic, biochemical, histological and clinical characteristics of patients

	Total cohort (n = 632)
Greek/Hungarian, n (%)	366/266 (57.9/42.1)
Age, median (IQR), yr	56.5 (17)
Sex, male/female, n (%)	376/256 (59.5/40.5)
CHB/CHC/Alcoholic/PBC+PSC/AIH/other, n	203/183/198/28/15/5
GP73, median (IQR), units, (ULN: 20 units)	17.3 (20.4)
GP73, pos/neg, n (%)	277/355 (43.8/56.2)
INR, median (IQR), (normal: 0.85-1.15)	1.15 (0.33)
Platelets, median (IQR), x103/μL	153 (114)
AST, median (IQR), (ULN: 40 U/L)	50 (54)
ALT, median (IQR), (ULN: 40 U/L)	40 (44)
γ-GT, median (IQR), (ULN: 37 U/L)	62 (113)
ALP, median (IQR), (ULN: 104 U/L)	95 (77)
Bilirubin, median (IQR), (ULN: 1.1 mg/dL)	1.2 (1.7)
Albumin, median (IQR), (normal: 3.5-5.2 g/dL)	3.9 (1.3)
AFP, median (IQR), (ULN: 10 ng/ml)	4 (6.1)
Fibrosis METAVIR stage, (F0, F1/≥ F2, n (%)	96/100 (49/51)
Cirrhosis, yes/no, n (%)	450/182 (71.2/28.8)
Decompensation of cirrhosis, yes/no, n (%)	226/224 (50.2/49.8)
HCC, yes/no, n (%)	79/553 (12.5/87.5)
HCC BCLC stage, 0/A/B/C/D1, n (%)	2/23/22/21/10 (2.6/29.5/28.2/26.9/12.8)
HCC BCLC stage, 0-A-B/C-D1, n (%)	47/31 (60.3/39.7)
HCC dimensions (very early/intermediate/advanced)	2/32/44 (2.6/41/56.4)
Follow-up ≥ 6 mo, yes/no, n (%)	479/153 (75.8/24.2)
Duration of follow-up, median (IQR), mo	50 (57)

¹One missing case because diagnosis set on autopsy. IQR: Interquartile range; GP73: Golgi protein 73; ULN: Upper limit of normal; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; AIH: Autoimmune hepatitis; INR: International normalized ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GT: γ-glutamyl transpeptidase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; BCLC: Barcelona clinic liver cancer.